Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis

AIMS: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are the recommended first injectable therapy in type 2 diabetes. However, long‐term persistence is suboptimal and partly attributable to gastrointestinal tolerability, particularly during initiation/escalation. Gradual titration of fixed‐ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Rayner, Christopher K., Wu, Tongzhi, Aroda, Vanita R., Whittington, Craig, Kanters, Steve, Guyot, Patricia, Shaunik, Alka, Horowitz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756611/
https://www.ncbi.nlm.nih.gov/pubmed/32991041
http://dx.doi.org/10.1111/dom.14202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756611/
https://www.ncbi.nlm.nih.gov/pubmed/32991041
http://dx.doi.org/10.1111/dom.14202

Ejemplares similares